Abstract:In a recent issue of CHEST (January 2013), Durmowicz et al 1 highlight the fi nding that despite improvement in both cystic fi brosis (CF) transmembrane conductance regulator (CFTR) and pulmonary function in clinical trials of ivacaftor (recently approved by the US Food and Drug Administration for individuals with CF and the G551D mutation), there does not appear to be a direct correlation between changes in sweat chloride (a measure of CFTR function) and changes in FEV 1 (an established effi cacy measure). They also were unable to identify a minimum threshold for change in sweat chloride that was associated with FEV 1 improvement. Despite the fi ndings, lack of a linear correlation between the changes in these outcome measures should not diminish the potential utility of sweat chloride for predicting clinical outcomes. Although the data presented failed to show a population level threshold for change in sweat chloride, the absolute sweat chloride concentrations after treatment in the two ivacaftor trials were not assessed. While adult sweat chloride values are highly variable across CF and healthy control subjects, 2 concentrations , 60 mM are typical among individuals without CF, and intermediate values are associated with a more benign clinical course. In reanalysis of the ivacaftor trial data, Seliger et al 3 show that nearly every participant has a resulting sweat chloride u0002 80 mM after 2 weeks of treatment, which does not provide the spectrum of response required to readily establish a linear correlation with another outcome. Thus, correlation between changes in sweat chloride and change in FEV 1 may not fully capture the predictive ability of sweat chloride. There is no doubt that FEV 1 variability across and within individuals poses a challenge for clinical research in CF. That variability comes from years of infection, infl ammation, and structural damage to the lung and can confound treatment effects. Before a meaningful quantitative relationship between CFTR activity and lung function or other clinical outcomes can be established, more work must be done to better understand the complex collection and interaction of physiologic and clinical measures in CF, particularly across diverse patient populations. The evaluation of younger patient populations with mild disease (and for whom lung function cannot be reliably measured nor acute changes expected) poses a particular challenge and highlights the need for robust pharmacodynamic parameters predictive of clinical response. Further discussions between regulatory agencies, trial sponsors, and community advocates will be necessary for monitoring the evolution of biomarkers in the regulatory approval process to ensure availability of benefi cial and safe therapies. Editor’s Note: Authors are invited to respond to Correspondence that cites their previously published work. Those responses appear after the related letter. In cases where there is no response, the author of the original article declined to respond or did not reply to our invitation. Sonya L. Heltshe , PhD Nicole Mayer-Hamblett , PhD Seattle, WA Steven M. Rowe , MD, MSPH Birmingham, AL

Understanding the relationship between sweat chloride and lung function in cystic fibrosis.

Elucidation of oil-in-water emulsions stabilized with celery cellulose

Extraction of cellulose nanocrystalline from Camellia oleifera Abel waste shell: Study of critical processes, properties and enhanced emulsion performance

Cellulose nanofibrils-stabilized food-grade Pickering emulsions: Clarifying surface charge's contribution and advancing stabilization mechanism understanding

Pickering emulsion stabilized with fibrous nanocelluloses: Insight into fiber flexibility-emulsifying capacity relations

In vitro gastrointestinal digestibility of corn oil-in-water Pickering emulsions stabilized by three types of nanocellulose

Influence of Ultrasonic on the Flow Behavior and Disperse Phase of Cellulose Nano-particles at Fluid–Fluid Interface

Cellulose nanofibers produced from spaghetti squash peel by deep eutectic solvents and ultrasonication

Pickering emulsion stabilized by cellulosic fibers: Morphological properties-interfacial stabilization-rheological behavior relationships

Fabrication and characterization of sunflower oil-in-water emulsions stabilized with sunflower stem pith cellulose nanofibril

Fabrication of edible nanocellulose chitosan bi-component film based on a novel "swell-permeate" approach

Improvement of low-oil gelatin emulsions performance by adjusting the electrostatic interaction between gelatin and nanocellulose with different morphologies

A strategic marketing approach to reduce health plan disenrollment.

Impact of hydrophobically modified cellulose nanofiber on the stability of Pickering emulsion containing insect protein

The Use of Corn Stover-Derived Nanocellulose as a Stabilizer of Oil-in-Water Emulsion

Conformational changes induced by cellulose nanocrystals in collaboration with calcium ion improve solubility of pea protein isolate

High throughput disassembly of cellulose nanoribbons and colloidal stabilization of gel-like Pickering emulsions

Camellia Oleifera shells derived nano cellulose crystals conjugated with gallic acid as a sustainable Pickering emulsion stabilizer

In Vitro Gastrointestinal Digestion of Corn-Oil-in-Water Pickering Emulsions: Influence of Lignin-Containing Cellulose Nanofibrils Loading

Pickering emulsions co-stabilised by cellulose nanofibres and nicotinamide mononucleotide

Properties of Pickering emulsions stabilized by cellulose nanocrystals extracted from litchi peels